These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 29023092)
1. Effect of the Flexible Regions of the Oncoprotein Mouse Double Minute X on Inhibitor Binding Affinity. Qin L; Liu H; Chen R; Zhou J; Cheng X; Chen Y; Huang Y; Su Z Biochemistry; 2017 Nov; 56(44):5943-5954. PubMed ID: 29023092 [TBL] [Abstract][Full Text] [Related]
2. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors. Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721 [TBL] [Abstract][Full Text] [Related]
3. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792 [TBL] [Abstract][Full Text] [Related]
5. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571 [TBL] [Abstract][Full Text] [Related]
6. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99. Lee XA; Verma C; Sim AYL Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639 [TBL] [Abstract][Full Text] [Related]
7. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation. Chen J; Wang J; Zhang Q; Chen K; Zhu W Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018 [TBL] [Abstract][Full Text] [Related]
8. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors. Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542 [TBL] [Abstract][Full Text] [Related]
9. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197 [TBL] [Abstract][Full Text] [Related]
10. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells. Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697 [TBL] [Abstract][Full Text] [Related]
11. Molecular basis for the inhibition of p53 by Mdmx. Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582 [TBL] [Abstract][Full Text] [Related]
12. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX. Lu SY; Jiang YJ; Zou JW; Wu TX J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342 [TBL] [Abstract][Full Text] [Related]
13. Monitoring Ligand-Induced Protein Ordering in Drug Discovery. Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay. Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660 [TBL] [Abstract][Full Text] [Related]
15. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450 [TBL] [Abstract][Full Text] [Related]
16. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. Chen J; Zhang D; Zhang Y; Li G Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446 [TBL] [Abstract][Full Text] [Related]
17. Application of binding free energy calculations to prediction of binding modes and affinities of MDM2 and MDMX inhibitors. Lee HS; Jo S; Lim HS; Im W J Chem Inf Model; 2012 Jul; 52(7):1821-32. PubMed ID: 22731511 [TBL] [Abstract][Full Text] [Related]
18. A site-directed mutagenesis study of the MdmX RING domain. Egorova O; Mis M; Sheng Y Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078 [TBL] [Abstract][Full Text] [Related]
19. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations. Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361 [TBL] [Abstract][Full Text] [Related]
20. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor. Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]